Revolutionizing Hypertension Management: Cutting-Edge Microneedle Patch Infused with Zinc Oxide Nanoparticles for Advanced Transdermal Drug Delivery

Transdermal drug delivery methods prove markedly superior to oral or hypodermic alternatives. By circumventing first-pass medication metabolism and gastrointestinal breakdown, these methods afford patients increased convenience through a minimally invasive and painless process. A cutting-edge transdermal drug delivery device has emerged, combining nanoparticles with dissolving microneedles. This innovative technique seeks to elevate the transdermal administration of losartan potassium and hydrochlorothiazide (HCTZ). The optimized formulation demonstrated excellent results with 100 needles measuring 575 μm in length and a pointed end. FTIR confirmed ingredient compatibility, while PXRD indicated the amorphous nature of the drug, suggesting improved bioavailability. DSC and TGA verified the thermal stability of both formulations. Release studies exhibited a rapid release behavior from MNP-6, with 82.11% of losartan and 81.50% HCTZ released within 30 min, following a zero-order kinetics pattern confirming a controlled drug delivery system. Histopathological findings supported the biocompatibility of the developed formulations, indicating its potential as a transdermal delivery system for losartan and HCTZ. This drug-loaded nanoparticle-based microneedle patch holds promise for achieving improved bioavailability and a prompt response to elevated blood pressure, leading to effective hypertension management.